市场调查报告书
商品编码
1249921
全球体外诊断市场:按产品、按测试、按应用、按最终用户和预测,2023-2032 年In-vitro Diagnostics Market - By Product, By Test, By Application, By End-user & Forecast, 2023 - 2032 |
由于医疗保健基础设施的持续改进以及政府和私人病理实验室的增加,体外诊断市场预计将从 2023 年到 2032 年显着增长。
此外,增加政府举措(例如资助诊断中心和支持开发更新、技术更先进的体外诊断设备)预计将在预计期间促进行业扩张。
总体而言,体外诊断行业按产品、测试、应用、最终用途和地理位置进行细分。
由于诊断设备在医疗保健领域的应用不断扩大,设备领域有望在 2032 年大幅增长。 诊断测试广泛用于检测多种疾病和进行常规健康检查。 此外,快速扩张的医疗保健市场和医疗保健投资的激增预计也将促进这一领域的增长。 顺便说一句,美国的医疗保健支出将在 2021 年增长 2.7%,达到 4.3 万亿美元的惊人规模。
从考试领域来看,临床化学领域预计从 2023 年到 2032 年将呈现显着增长。 在药物发现开发中越来越多地使用临床化学正在推动该行业的扩张。 体外诊断自动化的引入也有望对该领域的增长产生积极影响。
根据应用,到 2032 年,糖尿病行业的价值预计将超过 210 亿美元。 预计在糖尿病预防和管理方面的努力和资金的增加将推动体外诊断市场。 糖尿病的早期诊断和检测使该疾病更易于管理并改善患者预后。
按最终用途划分,预计学术和研究机构在预测期内的复合年增长率将超过 2.5%。 体外诊断 (IVD) 在学术和研究机构中极为重要,因为它们允许科学家和研究人员在受控环境中研究和分析生物样本。 此外,越来越多的研发项目以及学术和研究机构越来越多地使用分子诊断来分析药物安全性和敏感性,将进一步推动该领域的发展。
按地区划分,到 2032 年,欧洲体外诊断市场估计将超过 320 亿美元。 公共机构和私营公司增加的床旁分子诊断教育活动正在促进该地区的市场增长。 此外,预计医疗诊断设备的技术创新将进一步推动市场增长。
In-vitro Diagnostics Market is anticipated to grow significantly from 2023 to 2032, owing to the constant improvements in the healthcare infrastructure and the increasing number of government and privately owned pathology labs. Besides, growing initiatives taken by the governments, such as funding diagnostic centers and supporting the development of newer, technologically advanced in-vitro devices, are expected to favor industry expansion during the estimated timeframe.
Overall, the in-vitro diagnostics industry is segmented in terms of product, test, application, end-use, and region.
Based on product, the instruments segment will grow exponentially during 2032 owing to the increasing application of diagnostic instruments in the healthcare sector. Diagnostic testing is widely used to detect several conditions and for routine health checkups. Moreover, the rapidly expanding healthcare market and constantly surging investments in healthcare will further contribute to segmental growth. For the record, the US health spending increased by 2.7% in 2021, reaching a whopping USD 4.3 trillion.
By test, the clinical chemistry segment will showcase considerable growth during 2023-2032. The mounting use of clinical chemistry in drug discovery and development will support the industry expansion. In addition, introduction to automation in the in-vitro diagnostic devices will also positively influence segmental growth.
Considering the application, the diabetes segment is anticipated to be valued at over USD 21 billion by 2032. Increasing initiatives and funding for diabetes prevention and management will drive the in-vitro diagnostics market. Early diagnosis and detection of diabetes can result in managing the disease better and offer enhanced patient outcomes.
In terms of end-use, the academic & research institutes segment will exhibit over 2.5% CAGR during the forecast time. In vitro diagnostics (IVD) is crucial in academic and research institutes as it empowers scientists and researchers to study and analyze biological samples in a controlled environment. Besides, the increasing number of research and development projects, along with the budding use of molecular diagnostics in analyzing drug safety and sensitivity in academic and research institutes, will further augment segmental growth.
Regionally, the Europe in-vitro diagnostics market is estimated to be valued at over USD 32 billion by 2032. Increasing efforts made by public and private organizations to spread awareness regarding point-of-care molecular diagnostics will contribute to the regional market growth. Besides, the rising technological innovations across medical diagnostic devices will further boost market growth.